Telepathy Trademark: An In-Depth Legal Analysis of Neuralink’s Trademark Dispute

Introduction & Overview

The telepathy trademark battle represents one of the most fascinating legal conflicts in modern technology. Neuralink, Elon Musk’s groundbreaking brain-computer interface company, has filed trademark applications that could reshape how we think about mind-controlled technology.

Neuralink stands at the forefront of neural technology innovation. The company develops cutting-edge brain-computer interfaces that promise to revolutionize human interaction with digital devices. Elon Musk’s vision extends far beyond simple medical applications, aiming to create seamless connections between human thoughts and external technology.

A brain-computer interface is “a direct communication pathway between a brain and an external device.” Neuralink’s ambitious goal involves enabling thought-controlled operation of software and hardware through implantable devices. This technology could allow paralyzed individuals to control computers using only their minds.

The Neuralink trademark strategy includes recent applications for both “Telepathy” and “Telekinesis.” These filings represent crucial steps in protecting the company’s intellectual property as it advances toward commercial deployment.

On March 3, 2025, Neuralink filed “intent-to-use” trademark applications with the USPTO. The telepathy trademark application carries serial number 99063908. Neuralink describes “Telepathy” as “an implantable brain-to-computer interface for facilitating communication and control of software and hardware.”

However, the path to securing these trademarks faces significant legal obstacles. Competing claims from another company have created a complex trademark law scenario that could impact Neuralink’s branding strategy.

The Elon Musk brain implant technology represents more than medical innovation. It embodies a vision where humans seamlessly integrate with digital systems through direct neural connections. This ambitious goal requires not only technological breakthroughs but also careful legal navigation.

Source: USPTO filing details

🚀 Unlock Your Business Potential

*Inspired by innovations in brain-computer interfaces? Imagine what automation can do for your business’s connectivity and control. Stop manually wrestling with tasks and let Flowgrammer build your bridge to maximum efficiency.*

Explore Automation Solutions

Detailed Analysis of Neuralink’s Trademark Applications

The telepathy trademark filing strategy reveals Neuralink’s sophisticated approach to intellectual property protection. Understanding the technical and legal aspects requires examining both the application process and its implications under current trademark law.

Intent-to-Use Applications Explained

Neuralink filed “intent-to-use” applications for both trademarks. This legal mechanism allows companies to secure trademark rights before actually using the mark in commerce. The approach proves particularly valuable for technology companies developing products that may take years to reach market.

An “intent-to-use” filing establishes priority while providing time for product development. Companies must demonstrate actual commercial use within specific timeframes to maintain their rights. This system balances innovation timelines with trademark protection requirements.

Technical Filing Details

The telepathy trademark application (serial number 99063908) was filed on March 3, 2025. Neuralink’s description emphasizes the implantable nature of their brain-computer interface technology. The filing specifically mentions facilitating “communication and control of software and hardware.”

The telekinesis patent application followed similar timing and structure. Both applications reflect Neuralink’s comprehensive approach to protecting terminology associated with mind-controlled technology.

Neuralink’s trademark law strategy becomes complex due to prior activity by competing companies. The timing of these filings creates potential conflicts that require careful legal navigation.

Commercial Use Requirements

USPTO guidelines require companies to prove actual commercial use within three years of acceptance. This requirement creates opportunities for competing applications if original filers fail to meet deadlines.

According to coverage on trademark strategy from IndieLaw, Neuralink’s pathway might be cleared if its competitor fails to demonstrate commercial use within the required timeframe. This possibility adds strategic importance to timing and commercial deployment plans.

The Neuralink trademark applications benefit from the company’s advanced clinical trial progress. Real-world testing provides strong evidence of intended commercial use, strengthening their legal position.

Serial numbers and filing dates establish priority sequences crucial for resolving conflicts. Neuralink’s March 2025 filings create specific timeline requirements that could determine ultimate trademark ownership.

Sources: USPTO filing details, IndieLaw trademark strategy coverage

The Trademark Conflict – Prophetic Versus Neuralink

The telepathy trademark dispute centers on competing claims between Neuralink and Prophetic, a lucid dreaming startup. This conflict illustrates the challenges emerging technologies face in securing distinctive branding rights.

Prophetic’s Background and Strategy

Prophetic operates as a prophetic lucid dreaming company focused on “non-invasive neuromodulation” wearables. The company aims to achieve “a radical transformation of the human experience” through devices designed to help people achieve lucid dreaming states.

Wesley Berry, a computer scientist, owns Prophetic and filed prior trademark applications. The company’s approach differs significantly from Neuralink’s invasive implant technology, focusing instead on external wearable devices.

Prophetic’s vision involves transforming sleep experiences through targeted neuromodulation. This approach contrasts sharply with Neuralink’s direct brain implant methodology, yet both companies seek similar trademark protection.

Timeline of Competing Filings

Prophetic filed its telepathy trademark application in 2023, predating Neuralink’s March 2025 filing. The company also filed for “Telekinesis” during summer 2024, again preceding Neuralink’s applications.

The USPTO accepted Prophetic’s “Telepathy” application in December 2024. Their telekinesis patent application received acceptance in August 2025. These acceptances establish Prophetic’s priority position in the trademark conflict.

However, acceptance differs from final registration. Prophetic must demonstrate actual commercial use within three years of acceptance to secure full trademark rights. This requirement creates potential opportunities for Neuralink.

Legal Implications and Opportunities

Trademark law requires proof of actual commercial use for final registration. If Prophetic fails to demonstrate commercial use within required timeframes, their applications would be considered abandoned.

Abandoned applications allow subsequent filers to claim priority. Neuralink’s telepathy trademark application could advance if Prophetic cannot prove commercial deployment of their lucid dreaming technology.

The conflict represents more than simple name disputes. Both companies develop neural interface technologies, creating legitimate trademark confusion concerns. However, their different approaches (invasive versus non-invasive) may allow coexistence in different market segments.

Industry observers note that while this represents a branding challenge for Neuralink, it may not significantly impact core product development. Alternative naming strategies could resolve conflicts without affecting technological advancement.

The involvement of Wesley Berry adds complexity to legal analysis. His background and Prophetic’s development timeline become crucial factors in determining commercial use requirements.

Sources: Envisage.Law analysis by Anthony J. Biller, The Debrief’s technology reporting

Future Implications and Clinical Developments

The telepathy trademark dispute unfolds against impressive clinical developments that demonstrate Neuralink’s technological capabilities. These advances strengthen the company’s position regardless of trademark outcomes.

Groundbreaking Human Trials

Neuralink’s first human trial began in January 2024 with participant Noland Arbaugh, a quadriplegic individual. The Noland Arbaugh Neuralink trial demonstrated remarkable success, with the participant reporting the ability to play video games using only his mind.

This breakthrough validated core brain-computer interface concepts that underpin Neuralink’s trademark applications. Real-world success strengthens legal arguments about intended commercial use and technological feasibility.

Arbaugh expressed gratitude for the positive impact on his life, providing powerful testimony about the technology’s potential. Such outcomes support Neuralink’s vision of enabling paralyzed individuals to control computers through thought alone.

Recent Clinical Expansions

UHN’s Toronto Western Hospital hosted two additional procedures on August 27, 2025, and September 3, 2025. These procedures involved patients living with spinal cord injuries and evaluated both safety and functionality of Neuralink’s wireless brain-computer interface device.

The expansion to multiple patients demonstrates Neuralink’s commitment to rigorous clinical testing. Such progress supports commercial use arguments in trademark disputes while advancing toward regulatory approval.

These clinical developments occur alongside the Elon Musk brain implant publicity, creating momentum for broader public acceptance. Success in medical applications provides foundation for eventual consumer market expansion.

Technology Beyond Medical Applications

Neuralink’s vision extends beyond medical treatment to general human-computer interaction enhancement. The telepathy trademark reflects ambitions for thought-controlled communication with electronic devices and potentially between humans with implants.

Related trademark applications include “Blindsight,” technology aimed at restoring vision to those with sight loss. This broader intellectual property strategy reveals Neuralink’s comprehensive approach to neural interface applications.

Strategic Alternatives and Innovation Priority

The trademark dispute may be navigated through alternative branding strategies if necessary. Innovation and patient outcomes remain Neuralink’s primary focus, with naming conventions being secondary considerations.

Clinical trial success provides strong evidence of actual technology development, distinguishing Neuralink from companies making speculative trademark claims. This real-world progress strengthens legal positions in trademark conflicts.

The company’s advancement continues unabated despite legal challenges, illustrating that technological innovation can proceed independently of branding disputes. Patient safety and treatment efficacy take priority over trademark concerns.

Sources: FirstWord HealthTech clinical reporting, UHN Toronto Western Hospital procedure details

Conclusion

The telepathy trademark battle between Neuralink and Prophetic represents a fascinating intersection of cutting-edge technology and intellectual property law. While Neuralink faces legal challenges in securing its preferred trademark names, the company’s technological advancement continues to progress impressively.

Neuralink’s “intent-to-use” applications for “Telepathy” and “Telekinesis” reflect strategic thinking about brand protection in emerging technology markets. The conflict with prophetic lucid dreaming company Prophetic illustrates the competitive landscape surrounding neural interface terminology.

Despite trademark hurdles, Neuralink’s clinical successes with patients like Noland Arbaugh Neuralink trial participant demonstrate real-world applications that could redefine brain-computer interface technology. These achievements provide strong foundation for commercial use arguments in trademark law proceedings.

The broader implications extend beyond simple naming rights. As neural interface technology advances, trademark disputes may become increasingly common. Companies must balance legal strategy with innovation priorities to achieve long-term success.

Neuralink’s approach of continuing clinical development while pursuing trademark protection demonstrates sound strategic thinking. Alternative branding options exist if current applications fail, ensuring that technological progress remains unimpeded by legal challenges.

Frequently Asked Questions